Mereo Stock Today

MREO
 Stock
  

USD 1.35  0.20  17.39%   

Market Performance
15 of 100
Odds Of Distress
Less than 37
Mereo Biopharma is selling for 1.35 as of the 12th of August 2022. This is a 17.39% increase since the beginning of the trading day. The stock's open price was 1.15. Mereo Biopharma has about a 37 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Mereo Biopharma Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of October 2021 and ending today, the 12th of August 2022. Click here to learn more.
CUSIP
589492107
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of April 2019
Category
Healthcare
Classification
Health Care
ISIN
US5894921072
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. The company has 108.9 M outstanding shares of which 5.21 M shares are now shorted by private and institutional investors with about 0.76 trading days to cover. More on Mereo Biopharma Group

Moving together with Mereo Biopharma

0.68ACXPAcurx Pharmaceuticals Earnings Call  This WeekPairCorr

Moving against Mereo Biopharma

0.75AIRSAirsculpt Technologies Earnings Call  TodayPairCorr
0.7ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.66JPMJP Morgan Chase Fiscal Year End 13th of January 2023 PairCorr
0.65ACBAurora Cannabis Fiscal Year End 26th of September 2022 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Mereo Biopharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Mereo Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Mereo Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Mereo Biopharma is way too risky over 90 days horizon
Mereo Biopharma may become a speculative penny stock
Mereo Biopharma appears to be risky and price may revert if volatility continues
Mereo Biopharma Group currently holds about 94.3 M in cash with (5.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Mereo Biopharma has a frail financial position based on the latest SEC disclosures
Over 80.0% of the company shares are owned by institutional investors
Latest headline from www.marketbeat.com: Mereo BioPharma Group Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
CEODenise ScotsKnight
Fama & French Classification
Average Analyst Recommendation
Analysts covering Mereo Biopharma report their recommendations after researching Mereo Biopharma's financial statements, talking to executives and customers, or listening in on Mereo Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Mereo Biopharma Group. The Mereo consensus assessment is calculated by taking the average forecast from all of the analysts covering Mereo Biopharma.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Mereo Biopharma Group based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Mereo Biopharma Group financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares587.5 M544.5 M
Significantly Up
Increasing
Slightly volatile
Total Assets117.3 M126.4 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities43.2 M38.4 M
Moderately Up
Increasing
Slightly volatile
Current Assets83 M99.3 M
Fairly Down
Increasing
Very volatile
Current Liabilities14.3 M12.5 M
Fairly Up
Increasing
Slightly volatile
Total Debt19.7 M16.8 M
Fairly Up
Increasing
Slightly volatile
Return on Average Assets0.140.134
Sufficiently Up
Decreasing
Very volatile
Gross Margin0.460.46
Steady
Decreasing
Slightly volatile
Asset Turnover0.350.35
Steady
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Mereo Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Mereo Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Mereo Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mereo Biopharma's financial leverage. It provides some insight into what part of Mereo Biopharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Mereo Biopharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Mereo Biopharma deploys its capital and how much of that capital is borrowed.
Liquidity
Mereo Biopharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 16.76 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Mereo Biopharma Group has a current ratio of 7.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Mereo Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mereo Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mereo Biopharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mereo to invest in growth at high rates of return. When we think about Mereo Biopharma's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(5.65 Million)
Mereo Biopharma Group (MREO) is traded on NASDAQ Exchange in USA. It is located in One Cavendish Place and employs 49 people. Mereo Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 140.48 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mereo Biopharma's market, we take the total number of its shares issued and multiply it by Mereo Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Mereo Biopharma Group conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 108.9 M outstanding shares of which 5.21 M shares are now shorted by private and institutional investors with about 0.76 trading days to cover. Mereo Biopharma Group currently holds about 94.3 M in cash with (5.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Check Mereo Biopharma Probability Of Bankruptcy
Ownership
Mereo Biopharma Group holds a total of 108.9 Million outstanding shares. The majority of Mereo Biopharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mereo Biopharma Group to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mereo Biopharma Group. Please pay attention to any change in the institutional holdings of Mereo Biopharma as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Mereo Ownership Details

Mereo Stock Price Odds Analysis

What are Mereo Biopharma's target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Mereo Biopharma jumping above the current price in 90 days from now is about 24.54%. The Mereo Biopharma Group probability density function shows the probability of Mereo Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.0973. This indicates Mereo Biopharma Group market returns are very sensitive to returns on the market. As the market goes up or down, Mereo Biopharma is expected to follow. In addition to that, the company has an alpha of 2.2635, implying that it can generate a 2.26 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 1.35HorizonTargetOdds Above 1.35
75.40%90 days
 1.35 
24.54%
Based on a normal probability distribution, the odds of Mereo Biopharma to move above the current price in 90 days from now is about 24.54 (This Mereo Biopharma Group probability density function shows the probability of Mereo Stock to fall within a particular range of prices over 90 days) .

Mereo Biopharma Historical Income Statement

Mereo Biopharma Group Income Statement is one of the three primary financial statements used for reporting Mereo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Mereo Biopharma Group revenue and expense. Mereo Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Mereo Biopharma Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 44.2 Million. Selling General and Administrative Expense is expected to rise to about 16.8 M this year, although the value of Operating Income will most likely fall to (22.5 M). View More Fundamentals

Mereo Stock Against Markets

Picking the right benchmark for Mereo Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Mereo Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Mereo Biopharma is critical whether you are bullish or bearish towards Mereo Biopharma Group at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Mereo Biopharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Ceiling Movement Now

   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

Mereo Biopharma Corporate Directors

Mereo Biopharma corporate directors refer to members of a Mereo Biopharma board of directors. The board of directors generally takes responsibility for the Mereo Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Mereo Biopharma's board members must vote for the resolution. The Mereo Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Peter Bains - Non-Executive Independent DirectorProfile
Kunal Kashyap - Non-Executive DirectorProfile
Deepa Pakianathan - Non-Executive DirectorProfile
Paul Blackburn - Non-Executive Independent DirectorProfile

Invested in Mereo Biopharma Group?

You need to understand the risk of investing before taking a position in Mereo Biopharma. The danger of trading Mereo Biopharma Group is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Mereo Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Mereo Biopharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Mereo Biopharma Group is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
134.5 M
Return On Assets
-0.14
Return On Equity
0.35
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.